Bafna Pharmaceuticals Ltd
NSE:BAFNAPH
Cash Flow Statement
Cash Flow Statement
Bafna Pharmaceuticals Ltd
| Sep-2020 | Mar-2021 | Sep-2021 | Mar-2022 | Sep-2022 | Mar-2023 | Sep-2023 | Mar-2024 | Sep-2024 | Mar-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||
| Net Income |
47
|
58
|
119
|
73
|
19
|
118
|
177
|
73
|
3
|
42
|
88
|
|
| Depreciation & Amortization |
35
|
45
|
54
|
55
|
50
|
53
|
54
|
50
|
56
|
49
|
47
|
|
| Other Non-Cash Items |
(231)
|
(7)
|
(25)
|
(35)
|
(24)
|
16
|
33
|
30
|
34
|
52
|
56
|
|
| Cash Taxes Paid |
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
1
|
(4)
|
(4)
|
|
| Cash Interest Paid |
(0)
|
1
|
3
|
8
|
13
|
17
|
19
|
23
|
27
|
27
|
32
|
|
| Change in Working Capital |
(239)
|
(233)
|
(120)
|
(13)
|
(58)
|
(138)
|
(109)
|
(59)
|
50
|
79
|
(36)
|
|
| Cash from Operating Activities |
(389)
N/A
|
(136)
+65%
|
28
N/A
|
80
+187%
|
(14)
N/A
|
50
N/A
|
155
+213%
|
95
-39%
|
143
+50%
|
221
+55%
|
154
-30%
|
|
| Investing Cash Flow | ||||||||||||
| Capital Expenditures |
(30)
|
(61)
|
(66)
|
(75)
|
(117)
|
(82)
|
(57)
|
(158)
|
(212)
|
(219)
|
(290)
|
|
| Other Items |
335
|
8
|
7
|
21
|
36
|
7
|
(10)
|
8
|
8
|
7
|
21
|
|
| Cash from Investing Activities |
305
N/A
|
(54)
N/A
|
(59)
-10%
|
(54)
+8%
|
(81)
-49%
|
(75)
+8%
|
(67)
+10%
|
(151)
-124%
|
(204)
-36%
|
(212)
-4%
|
(269)
-27%
|
|
| Financing Cash Flow | ||||||||||||
| Net Issuance of Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Issuance of Debt |
(435)
|
124
|
19
|
(44)
|
136
|
119
|
(26)
|
15
|
22
|
38
|
136
|
|
| Other |
(47)
|
(1)
|
7
|
2
|
(13)
|
(17)
|
(19)
|
(23)
|
(27)
|
(27)
|
(32)
|
|
| Cash from Financing Activities |
72
N/A
|
123
+72%
|
26
-79%
|
(42)
N/A
|
123
N/A
|
102
-17%
|
(45)
N/A
|
(8)
+81%
|
(4)
+51%
|
11
N/A
|
104
+875%
|
|
| Change in Cash | ||||||||||||
| Net Change in Cash |
(13)
N/A
|
(67)
-434%
|
(5)
+93%
|
(16)
-226%
|
28
N/A
|
76
+171%
|
43
-43%
|
(64)
N/A
|
(65)
-2%
|
20
N/A
|
(11)
N/A
|
|
| Free Cash Flow | ||||||||||||
| Free Cash Flow |
(419)
N/A
|
(197)
+53%
|
(38)
+81%
|
5
N/A
|
(130)
N/A
|
(33)
+75%
|
98
N/A
|
(64)
N/A
|
(70)
-10%
|
3
N/A
|
(136)
N/A
|
|